يعرض 1 - 10 نتائج من 2,055 نتيجة بحث عن '"Advanced"', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 1
    تقرير
    Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

    المصدر: MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients With Tumors With AKT Mutations

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400251Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  2. 2
    تقرير
    Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

    المصدر: MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400238Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  3. 3
    تقرير
    Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

    المصدر: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400225Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  4. 4
    تقرير
    Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

    المصدر: MATCH Treatment Subprotocol Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients With LAG-3+ Tumors With Mismatch Repair Deficiency (MMR-d) After Progression on Anti-PD-1/PD-L1 Therapy

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400264Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  5. 5
    تقرير
    Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

    المصدر: MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390852Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  6. 6
    تقرير
    Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

    المصدر: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390826Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  7. 7
    تقرير
    Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

    المصدر: MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390865Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  8. 8
    تقرير
    Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

    المصدر: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 Amplification

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390839Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  9. 9
    تقرير
    Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

    المصدر: MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR Mutations

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06385496Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  10. 10
    تقرير
    Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

    المصدر: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients With Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06385483Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث